ATE356637T1 - Supramolekulare komplexe enthaltende arzneimittel - Google Patents

Supramolekulare komplexe enthaltende arzneimittel

Info

Publication number
ATE356637T1
ATE356637T1 AT99965967T AT99965967T ATE356637T1 AT E356637 T1 ATE356637 T1 AT E356637T1 AT 99965967 T AT99965967 T AT 99965967T AT 99965967 T AT99965967 T AT 99965967T AT E356637 T1 ATE356637 T1 AT E356637T1
Authority
AT
Austria
Prior art keywords
supramolecular complex
drugs containing
supramolecular complexes
containing supramolecular
administering
Prior art date
Application number
AT99965967T
Other languages
English (en)
Inventor
Mark E Davis
Hector Gonzalez
Suzie Sue Jean Hwang
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Application granted granted Critical
Publication of ATE356637T1 publication Critical patent/ATE356637T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99965967T 1998-12-04 1999-12-03 Supramolekulare komplexe enthaltende arzneimittel ATE356637T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11084798P 1998-12-04 1998-12-04
US12785699P 1999-04-05 1999-04-05

Publications (1)

Publication Number Publication Date
ATE356637T1 true ATE356637T1 (de) 2007-04-15

Family

ID=26808436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965967T ATE356637T1 (de) 1998-12-04 1999-12-03 Supramolekulare komplexe enthaltende arzneimittel

Country Status (7)

Country Link
EP (1) EP1133318B1 (de)
JP (1) JP2002531530A (de)
AT (1) ATE356637T1 (de)
AU (1) AU2162700A (de)
CA (1) CA2353552A1 (de)
DE (1) DE69935526T2 (de)
WO (1) WO2000033885A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
GB0018072D0 (en) * 2000-07-25 2000-09-13 Smith & Nephew Biodegradable supramolecular assemblies
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
AU2002368202B2 (en) * 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
DE10239531A1 (de) 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
EP2277551B1 (de) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
WO2004032862A2 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US20210039070A1 (en) * 2018-03-15 2021-02-11 Klawego Gmbh & Co. Kg Composite materials for the depletion of contaminants from solutions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230566B (it) * 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH05331074A (ja) * 1992-05-27 1993-12-14 Nippon Oil & Fats Co Ltd 薬物運搬体
JPH07316205A (ja) * 1994-03-30 1995-12-05 D D S Kenkyusho:Kk シクロデキストリン誘導体
JP3699141B2 (ja) * 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
DE19612768A1 (de) * 1996-03-29 1997-10-02 Basf Ag Cyclodextringruppen enthaltende Polymere, Verfahren zu ihrer Herstellung und ihre Verwendung
JPH10158195A (ja) * 1996-11-28 1998-06-16 Res Inst For Prod Dev 配位結合を利用した薬物−高分子複合体製剤の調製方法
EP1003555A1 (de) * 1997-04-23 2000-05-31 The University of Otago Kontrollierte freisetzung von opthalmischen zusammensetzungen
NZ500694A (en) * 1997-04-30 2001-09-28 Univ Minnesota Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers

Also Published As

Publication number Publication date
DE69935526T2 (de) 2007-11-22
AU2162700A (en) 2000-06-26
CA2353552A1 (en) 2000-06-15
EP1133318A1 (de) 2001-09-19
WO2000033885A1 (en) 2000-06-15
JP2002531530A (ja) 2002-09-24
DE69935526D1 (de) 2007-04-26
EP1133318B1 (de) 2007-03-14

Similar Documents

Publication Publication Date Title
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
BG101118A (en) Therapeutical compounds
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
CA2111836A1 (en) Spin-trapping pharmaceutical compositions and methods for use thereof
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
MY119375A (en) Treatment of tinnitus using neuroprotective agents
WO1999012532A3 (en) Piperidine derivatives against malaria
EP0934065A4 (de) Pharmazeutische zusammensetzung
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
DE69922017D1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
KR950016760A (ko) 치질 치료제
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
HU9802897D0 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EP0799618A3 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
SE9403905D0 (sv) New formulations
EE03205B1 (et) Ropivakaiini kasutamine valuvaigistina kasutatava ravimpreparaadi valmistamiseks
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
ATE233745T1 (de) Arzneistoffe
GEP20043377B (en) Pharmaceutical Complex

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1133318

Country of ref document: EP